Glenmark Pharmaceuticals USA to Launch Potassium Phosphates Injection in March 2026

Glenmark Pharmaceuticals Inc USA plans to launch Potassium Phosphates Injection USP in multiple strengths, including single-dose vials and pharmacy bulk packages, starting March 2026. The product is bioequivalent and therapeutically equivalent to Fresenius Kabi's reference drug. The US market for this injection recorded annual sales of approximately $50.7 million for the year ending January 2026. Glenmark aims to expand its institutional product portfolio and provide affordable alternatives, according to Marc Kikuchi, President Business Head, North America.